Paul Tudor Jones Glycomimetics Inc Transaction History

Tudor Investment Corp Et Al

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$2.69 - $4.24 $44,479 - $70,108	-16,535 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$3.07 - $5.0 $83,451 - $135,915	-27,183 Reduced 62.18%	16,535 $51,000
Q2 2020 Aug 14, 2020	SELL	$2.06 - $3.76 $18,459 - $33,693	-8,961 Reduced 17.01%	43,718 $164,000
Q1 2020 May 15, 2020	BUY	$1.83 - $5.41 $20,172 - $59,634	11,023 Added 26.46%	52,679 $120,000
Q4 2019 Feb 14, 2020	BUY	$4.03 - $6.5 $32,876 - $53,027	8,158 Added 24.35%	41,656 $220,000
Q3 2019 Nov 14, 2019	BUY	$2.8 - $12.85 $93,794 - $430,449	33,498 New	33,498 $144,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.